Roche Diagnostics Operations, Inc.

Hoffmann-la Roche Inc.

Roche Molecular Systems, Inc.

Ventana Medical Systems, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Michael Gerg

Michael Schraeml

Christian Scholz

Birgit Bossenmaier

Gerhard Niederfellner

Hans-Peter Josel

Herbert Andres

Hartmut Duefel

Guy Georges

David Casagolda Vallribera

Dieter Heindl

Wolfgang Schaefer

Michael Tacke

Christian Klein

Christoph Seidel

Johann Karl

Thomas Meier

Markus Roessler

Julia Riedlinger

Frank Kowalewsky

Martin Kaufmann

Richard John Buick

Monika Soukupova

Rupert Herrmann

Alfred Mertens

Elke Faatz

Stefan Dengl

Erasmus Huber

Claudio Sustmann

Leopold Von Proff

Patrick C Roche

Sebastian Dziadek

Volker Schmid

Christian Vogl

Thomas Schindler

Klaus Hirzel

Lars Hillringhaus

Carmen Peess

Bernhard Eckert

Marcus-Rene Lisy

Frank Kroner

Rupert Hermann

Edgar Voss

Werner Naser

Rosa Isabel Saez Diaz

Caroline Dorothea Hojer

Michael Schraemi

Magdelena Swiatek-de Lange

Bernhard Reis

Magdelena Swiatek-de-Lange

Florian Huber

Jan Van Dieck

Richard Buick

Michel Achille Edouard Theron

Christoph Rutz

Ana Patricia Bento Pereira Da Silva

Barbara Ecabert

Everson Nogoceke

Moritz Marcinowski

The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as discloed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.

Biotin-specific monoclonal antibody and use thereof

The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.

Binding agent and assay for PIVKA

The present invention relates to a method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto.

Method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto

Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.

Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery

The present invention concerns an in vitro method for measurement of 25-hydroxyvitamin D, wherein the potentially interfering compound 24,25-dihydroxyvitamin Dis blocked by a binding agent specifically binding to 24,25-dihydroxyvitamin Dand not binding to 25-hydroxyvitamin D.

Method for measurement of vitamin D

A bivalent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bivalent binding agent, and for use of the disclosed bivalent binding agent in histological staining procedures.

Detection of a posttranslationally modified polypeptide by a bivalent binding agent

The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.

HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2

Herein is reported a fusion polypeptide according to formula INH&#x2014;S&#x2014;X&#x2014;S&#x2014;COOH&#x2003;&#x2003;(formula I)whereinXcomprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide,S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and&#x2014; denotes a peptide bond,wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein Xis inserted in place of the insert-in-flap-domain of the second polypeptide.

Amino acid sequence presenting fusion polypeptide and its use

The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.

HER3 antigen binding proteins binding to the beta-hairpin of HER3

The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.

Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4

Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.

Antibody specifically binding to insulin-like growth factor-1

The present invention relates to isolated antibodies, or an antigen portions thereof, which bind to human HER3. The novel antibodies are of great utility since they allow for the sensitive and specific detection of human HER3. Detection of human HER3 is, e.g., possible in a tissue sample, even when such tissue sample is a formalin-fixed paraffin embedded tissue (FFPET) sample.

Antibodies specifically binding to HER3

Growing community of inventors

Munich, Germany

Michael Gerg